Literature DB >> 2228245

Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS.

H Loppnow1, P Libby, M Freudenberg, J H Krauss, J Weckesser, H Mayer.   

Abstract

Many pathological effects of gram-negative bacteria are produced by their cell wall-derived lipopolysaccharides (LPSs). Differing pathogenicity of gram-negative LPSs, however, may depend on their capacities to induce cytokines. Thus, we studied the lethal toxicity of four nonenterobacterial LPSs and compared it with their capacity to induce mononuclear cell (MNC)-derived interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Unstimulated MNC did not release these cytokines. LPS from the phototrophic strain Rhodobacter capsulatus 37b4 elaborated little toxicity in galactosamine-treated mice (10 micrograms of LPS per mouse was the 100% lethal dose [LD100]) and induced IL-1 and IL-6 release only at high concentrations (10 to 50 micrograms of LPS per ml). R. capsulatus LPS failed to induce TNF activity even at the highest concentration tested (100 micrograms of LPS per ml). In contrast, LPS derived from Pseudomonas diminuta NCTC 8545 or the nodulating species Bradyrhizobium lupini DSM 30140 and Rhizobium meliloti 10406 expressed lethal toxicity (LD100, 1,000, 100, and 10 ng per mouse, respectively) and induced IL-1 or IL-6 (10 to 100, 10, and 1 ng of LPS per ml, respectively) at concentrations 1,000- to 10,000-fold lower than effective levels of R. capsulatus LPS. LPSs from P. diminuta, B. lupini, and R. meliloti also stimulated TNF production and release. MNC accumulated cell-associated IL-1 activities under circumstances in which released activity was readily detected. The cells contained only scant IL-6 activity, indicating release of this mediator rather than intracellular accumulation. Antisera to the respective cytokines inactivated biological activities of the samples selectively. The R. capsulatus LPS inhibited cytokine induction by LPS from P. diminuta, B. lupini, and R. meliloti in coincubation experiments. These results show that the in vivo lethality of the LPSs tested correlates with the induction of monocyte-derived cytokines in vitro. The results of this study suggest that the different lethality of various LPSs from gram-negative bacteria may be due to the differential ability of these LPSs to induce cytokine production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228245      PMCID: PMC313723          DOI: 10.1128/iai.58.11.3743-3750.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

Review 1.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages.

Authors:  P A Murphy; P L Simon; W F Willoughby
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

5.  Purification and physico-chemical characterization of rabbit tumor necrosis factor.

Authors:  M R Ruff; G E Gifford
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

6.  Shock and tissue injury induced by recombinant human cachectin.

Authors:  K J Tracey; B Beutler; S F Lowry; J Merryweather; S Wolpe; I W Milsark; R J Hariri; T J Fahey; A Zentella; J D Albert
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

7.  Galactosamine-induced sensitization to the lethal effects of endotoxin.

Authors:  C Galanos; M A Freudenberg; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

Review 8.  Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils.

Authors:  H Z Movat; M I Cybulsky; I G Colditz; M K Chan; C A Dinarello
Journal:  Fed Proc       Date:  1987-01

9.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

10.  Pseudomonas diminuta LPS with a new endotoxic lipid A structure.

Authors:  N Kasai; S Arata; J Mashimo; Y Akiyama; C Tanaka; K Egawa; S Tanaka
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

View more
  37 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  The biology of endotoxin.

Authors:  H Heine; E T Rietschel; A J Ulmer
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

4.  Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14.

Authors:  H Loppnow; F Stelter; U Schönbeck; C Schlüter; M Ernst; C Schütt; H D Flad
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

5.  Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein.

Authors:  J Schletter; H Brade; L Brade; C Krüger; H Loppnow; S Kusumoto; E T Rietschel; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

Review 6.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

7.  Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice.

Authors:  L Masucci-Magoulas; P Moulin; X C Jiang; H Richardson; A Walsh; J L Breslow; A Tall
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 8.  Multivalent glycoconjugates as anti-pathogenic agents.

Authors:  Anna Bernardi; Jesus Jiménez-Barbero; Alessandro Casnati; Cristina De Castro; Tamis Darbre; Franck Fieschi; Jukka Finne; Horst Funken; Karl-Erich Jaeger; Martina Lahmann; Thisbe K Lindhorst; Marco Marradi; Paul Messner; Antonio Molinaro; Paul V Murphy; Cristina Nativi; Stefan Oscarson; Soledad Penadés; Francesco Peri; Roland J Pieters; Olivier Renaudet; Jean-Louis Reymond; Barbara Richichi; Javier Rojo; Francesco Sansone; Christina Schäffer; W Bruce Turnbull; Trinidad Velasco-Torrijos; Sébastien Vidal; Stéphane Vincent; Tom Wennekes; Han Zuilhof; Anne Imberty
Journal:  Chem Soc Rev       Date:  2012-12-19       Impact factor: 54.564

9.  Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist.

Authors:  S Kobayashi; T Kawata; A Kimura; K Miyamoto; K Katayama; I Yamatsu; D P Rossignol; W J Christ; Y Kishi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Legionella pneumophila growth restriction and cytokine production by murine macrophages activated by a novel Pseudomonas lipid A.

Authors:  S Arata; N Kasai; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.